Drug Insights

Is Risdiplam approved by the FDA?

5 July 2024
3 min read

Yes, risdiplam, marketed under the brand name Evrysdi, is FDA approved. Its FDA approval on August 7, 2020, has provided new hope and convenience for individuals affected by SMA, improving the management and quality of life for patients with this condition.

What is Risdiplam?

Risdiplam is a medication used to treat spinal muscular atrophy (SMA), a genetic disorder characterized by weakness and wasting of the muscles needed for movement. It is designed for use in both children and adults. The drug works by increasing the production of the survival motor neuron (SMN) protein, which is crucial for muscle function.

How Risdiplam Works

Risdiplam is a small molecule that modifies splicing of the SMN2 gene to increase the production of functional SMN protein. This protein is essential for the maintenance and survival of motor neurons.

Administration and Dosage

Risdiplam is administered orally once a day after a meal, at the same time each day. The dosage varies based on age and weight:

For adults and children 2 years and older:

  • Weight less than 20 kg: 0.25 mg/kg once daily
  • Weight 20 kg or more: 5 mg once daily

For children under 2 years:

  • Less than 2 months old: 0.15 mg/kg once daily
  • 2 months to less than 2 years: 0.2 mg/kg once daily

Risdiplam is supplied as a powder that must be reconstituted into a liquid form at a pharmacy. It should not be used in its powder form. The mixed liquid medicine should be stored in the refrigerator and can be kept at room temperature for a limited period.

Potential Side Effects

Risdiplam can cause various side effects, some of which can be serious. Common side effects include:

  • Fever
  • Lung infection
  • Vomiting
  • Diarrhea
  • Constipation
  • Rash
  • Cold symptoms (stuffy nose, sneezing, sore throat)

Serious side effects may include:

  • Pain or burning when urinating
  • Signs of a lung infection (fever, cough with mucus, chest pain, shortness of breath)

Precautions and Warnings

Risdiplam may harm an unborn baby, so effective birth control is necessary during treatment and for at least one month after the last dose. Women who are pregnant or planning to become pregnant should inform their healthcare provider. Additionally, risdiplam may affect fertility in men. Patients should not breastfeed while using risdiplam.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA authorizes Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb)
Latest Hotspot
2 min read
FDA authorizes Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb)
5 July 2024
Formycon AG, together with their licensing partner Klinge Biopharma GmbH, has disclosed that the FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, has received approval from the U.S. Food and Drug Administration.
Read →
Is Tafasitamab approved by the FDA?
Drug Insights
3 min read
Is Tafasitamab approved by the FDA?
5 July 2024
tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.
Read →
Ubix Therapeutics and Yuhan Announce Exclusive Licensing for Oral AR Degrader UBX-103 to Combat Advanced Prostate Cancer
Latest Hotspot
3 min read
Ubix Therapeutics and Yuhan Announce Exclusive Licensing for Oral AR Degrader UBX-103 to Combat Advanced Prostate Cancer
5 July 2024
Ubix Therapeutics and Yuhan unveil an exclusive licensing deal for UBX-103, an oral AR degrader to treat metastatic castration-resistant prostate cancer.
Read →
Is Brexucabtagene Autoleucel approved by the FDA?
Drug Insights
3 min read
Is Brexucabtagene Autoleucel approved by the FDA?
5 July 2024
Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.